Moderna reported third-quarter revenue of $1.3 billion, up 29% from $1.0 billion a year earlier, and posted net income of $162 million compared to a net loss of $200 million in the same quarter of 2025. The company raised its full-year 2026 revenue growth guidance to 15-25%, up from a previous expectation of up to 10% growth, citing momentum from the U.S. FDA approval of mFLUSIVA (its fifth approved product globally) and positive Phase 3 data for the cancer therapy intismeran.
Third-quarter revenue of $1.3 billion broke down as $780 million in the U.S. and $533 million internationally, driven primarily by higher COVID vaccine sales in international markets under long-term government partnerships. Cost of sales rose 54% to $318 million, including $65 million in third-party royalties, reflecting higher product volume and manufacturing costs. Research and development expenses fell 27% to $583 million, mainly from lower clinical development costs following completion of certain late-stage infectious disease studies. Selling, general and administrative expenses increased 5% to $282 million. Diluted earnings per share were $0.38, compared to a loss per share of $0.51 in the third quarter of 2025, a $362 million year-over-year improvement.
For full-year 2026, Moderna now expects revenue growth of 15-25%, with approximately half from U.S. markets and half from international. The company raised its year-end cash and investments outlook to $8.1 billion to $8.3 billion, up from a prior range of $4.7 billion to $5.2 billion. This increase reflects $2.6 billion in net proceeds from a convertible notes offering completed in September, partially offset by a $950 million litigation settlement payment to GSK announced in October and operational cash use. Research and development expenses for the full year are now expected at approximately $2.7 billion, reduced from a prior forecast of $2.9 billion. Capital expenditures are expected at approximately $0.2 billion, improved from a prior range of $0.2 billion to $0.3 billion.
What it means
Moderna’s turnaround from a $200 million quarterly loss to $162 million in profit rests on two distinct drivers: operational leverage from higher vaccine sales, and a one-time financing event. The 29% revenue growth in the quarter is real, COVID vaccine deliveries under government partnerships in international markets are recurring, not promotional. The 27% decline in R&D spending, however, reflects a structural shift: the company has completed or wound down certain late-stage infectious disease studies, meaning this cost reduction may not persist if new programs require enrollment. The cost of sales rose faster (54%) than revenue (29%), suggesting manufacturing efficiency has not yet caught up to volume; if this gap widens, gross margin will compress despite higher sales.
The raised full-year guidance to 15-25% growth is material, but the document does not state what drove the upward revision, whether it reflects stronger-than-expected Q3 performance, new partnership agreements, or revised assumptions about vaccine demand. The $2.6 billion convertible financing inflates the year-end cash balance substantially and provides runway, but it also introduces future dilution if the stock price remains above the conversion threshold. The company maintains a global valuation allowance against most deferred tax assets, meaning it has not yet demonstrated sustained profitability to tax authorities.
The intismeran Phase 3 data in melanoma (58% reduction in recurrence or death risk after six months, in combination with Merck’s KEYTRUDA) is positive, but the document states only that Moderna and Merck are “working toward regulatory submissions”, no timeline is given. The norovirus vaccine program did not meet statistical success criteria in its Phase 3 interim analysis, and the company has deferred a decision on the methylmalonic acidemia program pending results from propionic acidemia, suggesting resource constraints or caution about pipeline breadth.
What to watch
The next material disclosure will be the propionic acidemia pivotal data readout, expected in 2026 according to the filing. That result will signal whether Moderna’s rare disease programs can generate revenue outside infectious disease and oncology, and whether the R&D cost reductions announced this quarter are sustainable or temporary. Regulatory decisions on intismeran and the flu/COVID combination vaccine (mCOFLU) in the U.S. and additional markets will also test whether the raised revenue guidance reflects durable product diversification or dependence on COVID vaccine cycles.
Source: the company’s 8-K filed 2026-11-06 with the SEC.
For the standing yardsticks on Moderna: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Moderna.









